Patents by Inventor Masao Ohkuchi
Masao Ohkuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8398981Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: GrantFiled: October 19, 2011Date of Patent: March 19, 2013Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Patent number: 8394376Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: GrantFiled: December 7, 2010Date of Patent: March 12, 2013Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Patent number: 8226958Abstract: A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.Type: GrantFiled: March 25, 2004Date of Patent: July 24, 2012Assignees: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Toshihiro Nakashima, Takumi Sasaki, Kazuhiko Kimachi, Shigeki Kuwata, Tsukasa Nishihara, Atsuko Sakata, Masao Ohkuchi, Tomoyuki Koshi, Toshiyuki Edano
-
Publication number: 20120128694Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: ApplicationFiled: October 19, 2011Publication date: May 24, 2012Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYOInventors: TAKESHI IWATSUBO, TATSUHIKO KODAMA, TAKAO HAMAKUBO, TAISUKE TOMITA, IKUO HAYASHI, YASUOMI URANO, HIROKO IWANARI, MASAO OHKUCHI
-
Publication number: 20110165179Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: ApplicationFiled: December 7, 2010Publication date: July 7, 2011Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi IWATSUBO, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Patent number: 7947290Abstract: A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.Type: GrantFiled: December 22, 2009Date of Patent: May 24, 2011Assignees: Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Toshihiro Nakashima, Takumi Sasaki, Tsukasa Nishihara, Sumiyo Takemoto, Atsuko Sakata, Masao Ohkuchi, Tomoyuki Koshi, Toshiyuki Edano
-
Publication number: 20100166793Abstract: A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.Type: ApplicationFiled: December 22, 2009Publication date: July 1, 2010Applicants: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Toshihiro NAKASHIMA, Takumi Sasaki, Tsukasa Nishihara, Sumiyo Takemoto, Atsuko Sakata, Masao Ohkuchi, Tomoyuki Koshi, Toshiyuki Edano
-
Publication number: 20090270399Abstract: This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl, group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (substituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients.Type: ApplicationFiled: July 6, 2009Publication date: October 29, 2009Applicant: Kowa Co., Ltd.Inventors: Masao OHKUCHI, Yoshinori Kyotani, Hiromichi Shigyo, Tomoyuki Koshi, Takahiro Kitamura, Tadaaki Ohgiya, Takayuki Matsuda, Yukiyoshi Yamazaki, Natsuyo Kumai, Kyoko Kotaki, Hideo Yoshizaki, Yuriko Habata
-
Publication number: 20090220524Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: ApplicationFiled: April 23, 2007Publication date: September 3, 2009Applicants: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakuob, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Publication number: 20090143430Abstract: The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; W1 and W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.Type: ApplicationFiled: December 2, 2008Publication date: June 4, 2009Applicant: Kowa Co., Ltd.Inventors: Shigehiko IMAGAWA, Takeshi Doi, Masahiro Tamura, Masao Ohkuchi
-
Publication number: 20090069332Abstract: This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl, group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (substituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients.Type: ApplicationFiled: November 3, 2008Publication date: March 12, 2009Applicant: Kowa Co., Ltd.Inventors: Masao OHKUCHI, Yoshinori Kyotani, Hiromichi Shigyo, Tomoyuki Koshi, Takahiro Kitamura, Tadaaki Ohgiya, Takayuki Matsuda, Yukiyoshi Yamazaki, Natsuyo Kumai, Kyoko Kotaki, Hideo Yoshizaki, Yuriko Habata
-
Publication number: 20080119474Abstract: This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (substituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients.Type: ApplicationFiled: January 14, 2008Publication date: May 22, 2008Applicant: Kowa Co., Ltd.Inventors: Masao Ohkuchi, Yoshinori Kyotani, Hiromichi Shigyo, Tomoyuki Koshi, Takahiro Kitamura, Tadaaki Ohgiya, Takayuki Matsuda, Yukiyoshi Yamazaki, Natsuyo Kumai, Kyoko Kotaki, Hideo Yoshizaki, Yuriko Habata
-
Publication number: 20080003623Abstract: The present invention relates to a method of monitoring seriousness of hepatitis, comprising measuring GPC3 using an antibody which recognizes an N-terminal region of GPC3. According to the present invention, seriousness of hepatitis, specifically, progression of hepatitis or cirrhosis toward hepatoma can be presumed.Type: ApplicationFiled: October 3, 2005Publication date: January 3, 2008Inventors: Atsushi Nakajima, Hiroyuki Aburatani, Hiroko Iwanari, Masao Ohkuchi, Hirokazu Satoh
-
Patent number: 7314877Abstract: The present invention is directed to a compound represented by formula (1): (wherein R1 represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of R2 and R3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R2 and R3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-?) production inhibitory effect and improved absorption upon oral administration.Type: GrantFiled: March 3, 2004Date of Patent: January 1, 2008Assignee: Kowa Co., Ltd.Inventors: Seiichi Sato, Tomoyuki Koshi, Toshimi Mizoguchi, Kyoko Yasuoka, Natsuyo Kumai, Junko Totsuka, Masahiro Tamura, Masao Ohkuchi
-
Publication number: 20070208025Abstract: This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (substituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients.Type: ApplicationFiled: April 30, 2007Publication date: September 6, 2007Applicant: Kowa Co., Ltd.Inventors: Masao Ohkuchi, Yoshinori Kyotani, Hiromichi Shigyo, Tomoyuki Koshi, Takahiro Kitamura, Tadaaki Ohgiya, Takayuki Matsuda, Yukiyoshi Yamazaki, Natsuyo Kumai, Kyoko Kotaki, Hideo Yoshizaki, Yuriko Habata
-
Publication number: 20070166331Abstract: A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.Type: ApplicationFiled: March 28, 2003Publication date: July 19, 2007Applicants: Juridical Foundation The Chem-Sero-Therapeutic Research Institute, Kowa Company Ltd.Inventors: Toshihiro Nakashima, Takumi Sasaki, Kazuhiko Kimachi, Shigeki Kuwata, Tsukasa Nishihara, Atsuko Sakata, Masao Ohkuchi, Tomoyuki Koshi, Toshiyuki Edano
-
Publication number: 20070049595Abstract: This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients.Type: ApplicationFiled: November 1, 2006Publication date: March 1, 2007Applicant: Kowa Co., Ltd.Inventors: Masao Ohkuchi, Yoshinori Kyotani, Hiromichi Shigyo, Tomoyuki Koshi, Takahiro Kitamura, Tadaaki Ohgiya, Takayuki Matsuda, Yukiyoshi Yamazaki, Natsuyo Kumai, Kyoko Kotaki, Hideo Yoshizaki, Yuriko Habata
-
Publication number: 20060189621Abstract: The present invention is directed to a compound represented by formula (1): (wherein R1 represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of R2 and R3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R2 and R3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-?) production inhibitory effect and improved absorption upon oral administration.Type: ApplicationFiled: March 3, 2004Publication date: August 24, 2006Inventors: Seiichi Sato, Tomoyuki Koshi, Toshimi Mizoguchi, Kyoko Yasuoka, Junko Totsuka, Masahiro Tamura, Masao Ohkuchi
-
Publication number: 20060160804Abstract: This invention relates to pyridazine derivatives represented by the formula (1): wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients.Type: ApplicationFiled: March 22, 2006Publication date: July 20, 2006Applicant: Kowa Co., Ltd.Inventors: Masao Ohkuchi, Yoshinori Kyotani, Hiromichi Shigyo, Tomoyuki Koshi, Takahiro Kitamura, Tadaaki Ohgiya, Takayuki Matsuda, Yukiyoshi Yamazaki, Natsuyo Kumai, Kyoko Kotaki, Hideo Yoshizaki, Yuriko Habata
-
Publication number: 20060040986Abstract: The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; W1 and W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.Type: ApplicationFiled: December 5, 2003Publication date: February 23, 2006Applicant: Kowa Co., Ltd.Inventors: Shigehiko Imagawa, Takeshi Dol, Masahiro Tamura, Masao Ohkuchi